Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...
71.4% and 69.2% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0/1 versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%) at week 16 (p<0 ...
Scholastic's YouTube surge, 85M views, up 200%, signals a strategic shift, turning digital platforms into engines for ...
Envudeucitinib, another allosteric TYK2 inhibitor, also achieved PASI 75 in 70-75% of patients at 16 weeks and PGA 0/1 status ...
Takeda Pharmaceutical (NYSE:TAK) highlighted late-breaking Phase III data for investigational TYK2 inhibitor zasocitinib in ...
As cities worldwide accelerate toward electrification and decarbonization, the convergence of distributed energy resources and electric mobility is ...
AllAfrica on MSN
Police Take Over Training of Private Security Guards
In a significant policy shift aimed at strengthening national security and curbing the proliferation of what officials describe as "liberalized" private militias, the Uganda Police Force (UPF) has ...
As of March 30, government allocations from the state budget Reserve Fund, set at UAH 49.42 billion for 2026 and already ...
Alumis Inc. upgraded to Buy on strong Phase 3 psoriasis data for envudeucitinib, NDA plans, and upside valuation. Click here ...
Lilly's Ebglyss delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis: Indianapolis Monday, March 30, 2026, 12:00 Hrs [IST] ...
Global attention is riveted on West Asia, awaiting the outcome of a regime-change mission that appears to have gone astray.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results